Phase III Clinical Trials to treat ALS were announced by Brainstorm Therapeutics utilizing their successful NurOwn stem cell technology to treat amyotrophic lateral sclerosis (ALS). The company has received a $16 million grant from the California Institute for Regenerative Medicine [CIRM] to conduct the trial. The technology utilizes the patient’s own mesenchymal stem cells, which are differentiated to secrete neurotrophic factors that support the damaged neurons and aid the survival of other neurons. The stem cells are then injected directly into the muscle or spinal canal in order to deliver the cells directly to the areas most affected by ALS.
Previous successful trials have shown the safety and efficacy of the treatment, and this final stage of trials seeks to determine the extent to which the debilitating symptoms of ALS can be alleviated. “The support of this trial by the California Institute of Regenerative Medicine highlights the importance of addressing ALS’ unmet need beyond currently available therapies, which slow disease progression but do not maintain or restore function,” says the CEO of BrainStorm, Chiam Lebovits.
Advances in stem cell based regenerative treatments are creating more effective treatment options for patients suffering from a wide variety of disease, trauma and injury. To learn more about stem cells, and how families can bank their own valuable stem cells by recovering the very powerful dental pulp stem cells during routine dental procedures; such as wisdom teeth extractions or the during the loss of baby teeth, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here